Testing the CHAT Program for Patients With Heart Failure
Launched by WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY · May 20, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a program called CHAT, designed to help people with a specific type of heart failure known as Heart Failure with Preserved Ejection Fraction (HFpEF). The researchers want to see if using videos for education and having a health coach can help patients understand and manage their condition better. They are looking to find out if this approach is acceptable and effective for patients.
To participate in the trial, individuals must be at least 60 years old and have a confirmed diagnosis of HFpEF, which means they have symptoms of heart failure and a specific measurement of heart function that is normal. However, people who have been referred to hospice care, completed advance directives, or have significant dementia or mental health issues that would affect their ability to give consent cannot join the study. The trial is not yet recruiting participants, but it aims to provide valuable insights into how education and support can improve care for those living with HFpEF.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or Female ≥ 60 years old
- • 2. Documentation of HFpEF according to clinical practice guidelines (signs \& symptoms of HF AND ejection fraction ≥50%)
- Exclusion Criteria:
- • 1. Previously referred to hospice care
- • 2. Prior completion of advance directives
- • 3. Moderate-severe dementia or psychiatric disorder precluding informed consent.
About Weill Medical College Of Cornell University
Weill Medical College of Cornell University is a leading academic institution dedicated to advancing medical research and education. As a prominent sponsor of clinical trials, it focuses on innovative healthcare solutions and the development of new therapies across various medical disciplines. The institution is committed to fostering collaborative research efforts that enhance patient care and improve health outcomes. With a robust infrastructure and a team of experienced researchers and clinicians, Weill Cornell aims to translate scientific discoveries into practical applications, ensuring a strong emphasis on ethical standards and regulatory compliance throughout the clinical trial process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Parag Goyal, MD, MSc
Principal Investigator
Weill Medical College of Cornell University
Megan J Shen, PhD
Principal Investigator
Fred Hutchinson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported